CN1681789A - 1－吡啶－4－基－脲衍生物 - Google Patents

1－吡啶－4－基－脲衍生物 Download PDF

Info

Publication number
CN1681789A
CN1681789A CNA038219646A CN03821964A CN1681789A CN 1681789 A CN1681789 A CN 1681789A CN A038219646 A CNA038219646 A CN A038219646A CN 03821964 A CN03821964 A CN 03821964A CN 1681789 A CN1681789 A CN 1681789A
Authority
CN
China
Prior art keywords
urea
methyl
pyrrolidin
ethyl
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038219646A
Other languages
English (en)
Chinese (zh)
Inventor
哈米德·艾萨维
克里斯托弗·宾克特
鲍里斯·马泰斯
克劳斯·穆勒
奥利弗·奈勒
迈克尔·舍茨
托马斯·维勒
约尔格·维尔克尔
马丁·克劳泽尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1681789A publication Critical patent/CN1681789A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA038219646A 2002-09-17 2003-09-12 1－吡啶－4－基－脲衍生物 Pending CN1681789A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP02/10417 2002-09-17
EP0210417 2002-09-17

Publications (1)

Publication Number Publication Date
CN1681789A true CN1681789A (zh) 2005-10-12

Family

ID=32010909

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038219646A Pending CN1681789A (zh) 2002-09-17 2003-09-12 1－吡啶－4－基－脲衍生物

Country Status (13)

Country Link
US (1) US20060094716A1 (enExample)
EP (1) EP1554249A2 (enExample)
JP (1) JP2006505533A (enExample)
KR (1) KR20050043967A (enExample)
CN (1) CN1681789A (enExample)
AU (1) AU2003270186A1 (enExample)
BR (1) BR0314353A (enExample)
CA (1) CA2496624A1 (enExample)
MX (1) MXPA05002839A (enExample)
NO (1) NO20050932L (enExample)
RU (1) RU2005111589A (enExample)
WO (1) WO2004026836A2 (enExample)
ZA (1) ZA200502009B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102046603A (zh) * 2008-06-03 2011-05-04 埃科特莱茵药品有限公司 作为抗细菌剂的[4-(1-氨基-乙基)-环己基]-甲基-胺及[6-(1-氨基-乙基)-四氢-吡喃-3-基]-甲基-胺衍生物
CN106432039A (zh) * 2016-09-27 2017-02-22 南京工业大学 3,4‑二芳基马来酰亚胺衍生物及其制备方法与应用
CN107056673A (zh) * 2016-09-09 2017-08-18 南京工业大学 一种3,4‑二芳基马来酰亚胺衍生物及其制备方法与应用
CN107531589A (zh) * 2015-01-23 2018-01-02 Gvk生物科技私人有限公司 TrkA激酶抑制剂

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115290B (en) 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
AU2004212985B2 (en) 2003-02-20 2010-10-14 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
US7288538B2 (en) 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
WO2004078114A2 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
ATE440835T1 (de) 2003-03-06 2009-09-15 Glaxo Group Ltd Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
WO2004078744A2 (en) * 2003-03-07 2004-09-16 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
GB0305426D0 (en) 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
EP1608319A4 (en) 2003-04-03 2007-02-28 Univ California IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE
CN1856305B (zh) * 2003-09-26 2010-04-28 埃科特莱茵药品有限公司 用作尾加压素ⅱ拮抗剂的吡啶衍生物
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
CN101039930B (zh) * 2004-10-12 2010-08-11 埃科特莱茵药品有限公司 作为结晶硫酸盐的1-[2-(4-甲苯基-4-羟基-哌啶-1-基)-乙基]-3-(2-甲基-喹啉-4-基)-脲
ZA200703613B (en) 2004-10-20 2009-05-27 Univ California Improved inhibitors for the soluble epoxide hydrolase
EP1928821B1 (en) 2005-09-21 2009-01-07 Pfizer Limited Carboxamide derivatives as muscarinic receptor antagonists
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US8258301B2 (en) * 2007-05-15 2012-09-04 Boehringer Ingelheim International Gmbh Urotensin II receptor antagonists
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
MX2012010666A (es) * 2010-03-31 2012-10-05 Actelion Pharmaceuticals Ltd Derivados de isoquinolin-3-ilurea antibacterianos.
CN105622431A (zh) * 2011-01-28 2016-06-01 肯塔基大学研究基金会 茋类似物和治疗癌症的方法
CN110862398B (zh) * 2018-08-27 2021-04-06 北京赛特明强医药科技有限公司 脲取代的芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
FI4097099T3 (fi) 2020-02-07 2024-07-30 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
CN119219821A (zh) * 2024-12-03 2024-12-31 江苏金杉新材料有限公司 用于湿法冶金的苯乙烯系阴离子树脂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR016817A1 (es) * 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
AUPP003197A0 (en) * 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
AU2804400A (en) * 1999-02-12 2000-08-29 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
US6815451B2 (en) * 2001-03-27 2004-11-09 Actelion Pharmaceuticals Ltd. 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
CA2473892C (en) * 2001-12-04 2010-09-21 Actelion Pharmaceuticals Ltd Novel quinoline derivatives

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102046603A (zh) * 2008-06-03 2011-05-04 埃科特莱茵药品有限公司 作为抗细菌剂的[4-(1-氨基-乙基)-环己基]-甲基-胺及[6-(1-氨基-乙基)-四氢-吡喃-3-基]-甲基-胺衍生物
CN107531589A (zh) * 2015-01-23 2018-01-02 Gvk生物科技私人有限公司 TrkA激酶抑制剂
CN107056673A (zh) * 2016-09-09 2017-08-18 南京工业大学 一种3,4‑二芳基马来酰亚胺衍生物及其制备方法与应用
CN107056673B (zh) * 2016-09-09 2019-10-29 南京工业大学 一种3,4-二芳基马来酰亚胺衍生物及其制备方法与应用
CN106432039A (zh) * 2016-09-27 2017-02-22 南京工业大学 3,4‑二芳基马来酰亚胺衍生物及其制备方法与应用
CN106432039B (zh) * 2016-09-27 2019-02-22 南京工业大学 3,4-二芳基马来酰亚胺衍生物及其制备方法与应用

Also Published As

Publication number Publication date
ZA200502009B (en) 2005-11-01
JP2006505533A (ja) 2006-02-16
US20060094716A1 (en) 2006-05-04
MXPA05002839A (es) 2005-05-27
RU2005111589A (ru) 2006-01-20
AU2003270186A1 (en) 2004-04-08
CA2496624A1 (en) 2004-04-01
WO2004026836A2 (en) 2004-04-01
NO20050932L (no) 2005-04-15
BR0314353A (pt) 2005-07-19
WO2004026836A8 (en) 2005-05-12
EP1554249A2 (en) 2005-07-20
WO2004026836A3 (en) 2005-01-20
KR20050043967A (ko) 2005-05-11

Similar Documents

Publication Publication Date Title
CN1681789A (zh) 1－吡啶－4－基－脲衍生物
CN1288148C (zh) 作为尾加压素ii受体拮抗剂的1,2,3,4－四氢异喹啉的衍生物
CN1070492C (zh) 四环衍生物,制备方法和用途
CN1304390C (zh) 新颖的γ—分泌酶抑制剂
CN1136216C (zh) 吡啶酮羧酸衍生物或其盐以及以它们为有效成分的抗菌剂
CN1179960C (zh) 吲哚衍生物和其在治疗骨质疏松中的应用以及其它应用
CN1524079A (zh) 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
CN1617869A (zh) 作为尿压素ⅱ受体拮抗剂的4－(哌啶基－吡咯烷基－烷基－脲基)－喹啉类化合物
CN1535968A (zh) 四氢吡啶基或哌啶基杂环衍生物
CN1468216A (zh) 含氮五员环化合物
CN1454211A (zh) 作为Xa因子抑制剂的含氮杂双环化合物
CN1161334A (zh) 新的取代胍衍生物，其制备方法和其药物用途)
CN1678317A (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1235156A (zh) 新的苯并噻吩、苯并呋喃和吲哚化合物,它们的制备方法及含有它们的药物组合物
CN1102648A (zh) 取代的单-和双-吡啶基甲基吡啶酮类化合物
CN1072219C (zh) 二氮杂䓬酮、其生产和用途
CN1675184A (zh) 天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
CN1639119A (zh) 取代的2－氨基－环烷烃甲酰胺和它们作为半胱氨酸蛋白酶抑制剂的用途
CN1027368C (zh) 新型取代的喹啉衍生物的制备方法
CN1067053C (zh) 单环β－内酰胺类抗生素衍生物的中间体的制备方法
CN1856305A (zh) 吡啶衍生物及其作为尾加压素ⅱ拮抗剂的应用
CN1867555A (zh) 重排的戊醇,其制备方法以及它们作为抗炎药物的应用
CN1798744A (zh) 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
CN1503797A (zh) 吡啶并嘧啶或二氮杂萘衍生物
CN1780820A (zh) 作为阿立新受体拮抗剂的喹喔啉－3－酮衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication